Statins and influenza: Can we move forward?

Journal of Infectious Diseases

Volumn 205, Issue 1, 2012, Pages 1-3

  Walsh, Edward E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; MACROLIDE; PLACEBO; SIALIDASE INHIBITOR;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL THERAPY; BACTERIAL PNEUMONIA; CAUSE OF DEATH; CLINICAL TRIAL (TOPIC); DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INNATE IMMUNITY; LONG TERM CARE; MORBIDITY; MORTALITY; NOTE; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RESPIRATORY FAILURE; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA;

ANTIVIRAL AGENTS; CLIMATE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MYOCARDIAL INFARCTION; SIALIC ACIDS;

EID: 84555187500     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir693     Document Type: Note

References (32)

1. Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005; 165:265-72. (Pubitemid 40216277)
2. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7: 658-66. (Pubitemid 47444564)
3. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007; 357:1373-81. (Pubitemid 47535592)
4. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159-69. (Pubitemid 43202262)
5. Sasaki S, Sullivan M, Narvaez CF, et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest 2011; 121:3109-19.
6. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, doubleblind controlled phase 3 trial comparing the immunogenicity of high-dose and standarddose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172-80.
7. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor Oseltamivir in treating acute influenza (a randomized controlled trial). JAMA 2000; 283:1016-24. (Pubitemid 30112215)
8. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor Zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180:254-61. (Pubitemid 30256303)
9. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568-75. (Pubitemid 351411840)
10. Vandermeer M, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multi-state study. J Infect Dis 2011; 205:13-9.
11. Thompson WW, Weintraub E, Dhankhar P, et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respi Viruses 2009; 3:37-49.
12. Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR Morb MortalWkly Rep 2010; 59:1057-62.
13. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007; 131:1006-12. (Pubitemid 46608700)
14. Kwong JC, Li P, Redelmeier DA. Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS One 2009; 4:e8087.
15. Brett SJ, Myles P, Lim WS, et al. Preadmission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLoS One 2011; 6:e18120.
16. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007; 166:348-54. (Pubitemid 47216808)
17. JacksonML, Nelson JC,Weiss NS, Neuzil KM, Barlow W, Jackson LA. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet 2008; 372:398-405.
18. O'Neal HR Jr, Koyama T, Koehler EA, et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med 2011; 39:1343-50.
19. Viasus D, Garcia-Vidal C, Gudiol F, Carratala J. Statins for community-acquired pneumonia: current state of the science. Eur J Clin Microbiol Infect Dis 2010; 29:143-52.
20. Ballinger MN, Standiford TJ. Postinfluenza bacterial pneumonia: host defenses gone awry. J Interferon Cytokine Res 2010; 30:643-52.
21. Kaiser L, Fritz RS, Straus SE, Gubareva L, Hayden FG. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol 2001; 64: 262-8. (Pubitemid 32565121)
22. Zeiser R, Maas K, Youssef S, Durr C, Steinman L, Negrin RS. Regulation of different inflammatory diseases by impacting the mevalonate pathway. Immunology 2009; 127:18-25.
23. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19:571-82. (Pubitemid 44134311)
24. Corrales-Medina VF, Musher DM. Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review. J Infect 2011; 63:187-99.
25. Warren-Gash C, Bhaskaran K, Hayward A, et al. Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong. J Infect Dis 2011; 203: 1710-18.
26. Toschke AM, Heuschmann PU, Wood O, Wolfe CD. Temporal relationship between influenza infections and subsequent firstever stroke incidence. Age Ageing 2009; 38: 100-3.
27. Montecucco F, Mach F. Update on statinmediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol 2009; 31:127-42.
28. Fedson DS. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 2009; 3:129-42.
29. Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006; 43:199-205.
30. Terblanche M, Smith TS, Adhikari NK. Statins, bugs and prophylaxis: intriguing possibilities. Crit Care 2006; 10:168.
31. Carrillo-Esper R. Statins in influenza: time for a controlled clinical study. Cir Cir 2009; 77:351-2.
32. Burns KE, Chant C, Smith O, et al. A Canadian Critical Care Trials Group project in collaboration with the international forum for acute care trialists-Collaborative H1N1 Adjuvant Treatment pilot trial (CHAT): study protocol and design of a randomized controlled trial. Trials 2011; 12:70.